WittGen Biotechnologies
Turning single-cell clarity into cancer therapeutic opportunity through AI, WittGen develops a Single-Cell Cancer Drug Discovery & development Gen AI/ML Accelerator, LEIBER-X that boosts novel target/biomarker discovery, MoA monitoring and patient stratification, ensuring new drug success at cellular-level resolution. Our platform provides tailored companion diagnostics to optimize cancer treatment outcomes. Make Every Cell Counts!
Overview
WittGen Biotechnologies utilizes a single-cell RNA sequencing data analysis and testing to overcome the heterogeneity of cancer. The company offers services that includes prediction of subtypes, grade, and cell composition, SNV, CNV, cancer origin tracking, risk score with pathway analysis, drug recommendation, and novel biomarker identification. WittGen Biotechnologies was founded in 2023 and is based in Berkeley, California.
Tech Stack
Funding History
Seed Round
Undisclosed
Jun 2023
Plug and Play